Dr. Ravi had disclosed that he has received research funding from GlaxoSmithKline. Dr. Patel has disclosed that he is a consultant for Johnson & Johnson, CytRx Corporation, EMD Serono, Inc., Eli Lilly and Company, and Bayer. Mr. Sanford and Drs. Ross, Stephens, Miller, and Ali had disclosed that they are employees of and have equity interest in Foundation Medicine, Inc. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Fata F, O'Reilly E, Ilson D. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999;86:2034–2037.
Fury MG, Antonescu CR, Van Zee KJ. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005;11:241–247.
Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol 2010;22:351–355.
Agulnik M, Yarber JL, Okuno SH. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013;24:257–263.
Maki RG, D'Adamo DR, Keohan ML. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133–3140.
Frampton GM, Fichtenholtz A, Otto GA. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023–1031.
Guo T, Agaram NP, Wong GC. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007;13:4874–4881.
van der Graaf WT, Blay JY, Chawla SP. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879–1886.
Antonescu CR, Yoshida A, Guo T. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009;69:7175–7179.
Guo T, Zhang L, Chang NE. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer 2011;50:25–33.
von Mehren M, Randall RL, Benjamin RS. NCCN Clinical Practice Guidelines in Oncology; Soft Tissue Sarcoma. Version 2.2016. Accessed April 4, 2016. To view the most recent version of these guidelines, visit NCCN.org.
European Medicines Agency. CHMP assessment report: Votrient. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001141/WC500094275.pdf, Accessed April 3, 2016.
Kitagawa D, Yokota K, Gouda M. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 2013;18:110–122.
Ong P, Greulich S, Schumm J. Favorable course of pericardial angiosarcoma under Paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging. Circulation 2012;126:e279–281.